We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Novavax (NVAX) Stock Slides as Market Rises: Facts to Know Before You Trade
Read MoreHide Full Article
Novavax (NVAX - Free Report) closed at $6.36 in the latest trading session, marking a -2.15% move from the prior day. This move lagged the S&P 500's daily gain of 0.52%. On the other hand, the Dow registered a gain of 1%, and the technology-centric Nasdaq increased by 0.52%.
Shares of the vaccine maker have depreciated by 9.6% over the course of the past month, underperforming the Medical sector's gain of 3.5%, and the S&P 500's gain of 5.95%.
The investment community will be paying close attention to the earnings performance of Novavax in its upcoming release. The company's upcoming EPS is projected at -$0.12, signifying a 112.12% drop compared to the same quarter of the previous year. Our most recent consensus estimate is calling for quarterly revenue of $130.5 million, down 68.59% from the year-ago period.
Looking at the full year, the Zacks Consensus Estimates suggest analysts are expecting earnings of $2.65 per share and revenue of $1.07 billion. These totals would mark changes of +315.45% and +56.76%, respectively, from last year.
Investors might also notice recent changes to analyst estimates for Novavax. These revisions help to show the ever-changing nature of near-term business trends. Therefore, positive revisions in estimates convey analysts' confidence in the business performance and profit potential.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. To utilize this, we have created the Zacks Rank, a proprietary model that integrates these estimate changes and provides a functional rating system.
The Zacks Rank system, ranging from #1 (Strong Buy) to #5 (Strong Sell), possesses a remarkable history of outdoing, externally audited, with #1 stocks returning an average annual gain of +25% since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has moved 34.42% higher. As of now, Novavax holds a Zacks Rank of #3 (Hold).
Looking at valuation, Novavax is presently trading at a Forward P/E ratio of 2.45. For comparison, its industry has an average Forward P/E of 19.05, which means Novavax is trading at a discount to the group.
Investors should also note that NVAX has a PEG ratio of 0.06 right now. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company's expected earnings growth rate. The Medical - Biomedical and Genetics industry had an average PEG ratio of 1.35 as trading concluded yesterday.
The Medical - Biomedical and Genetics industry is part of the Medical sector. This group has a Zacks Industry Rank of 83, putting it in the top 34% of all 250+ industries.
The Zacks Industry Rank assesses the strength of our separate industry groups by calculating the average Zacks Rank of the individual stocks contained within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Make sure to utilize Zacks.com to follow all of these stock-moving metrics, and more, in the coming trading sessions.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Novavax (NVAX) Stock Slides as Market Rises: Facts to Know Before You Trade
Novavax (NVAX - Free Report) closed at $6.36 in the latest trading session, marking a -2.15% move from the prior day. This move lagged the S&P 500's daily gain of 0.52%. On the other hand, the Dow registered a gain of 1%, and the technology-centric Nasdaq increased by 0.52%.
Shares of the vaccine maker have depreciated by 9.6% over the course of the past month, underperforming the Medical sector's gain of 3.5%, and the S&P 500's gain of 5.95%.
The investment community will be paying close attention to the earnings performance of Novavax in its upcoming release. The company's upcoming EPS is projected at -$0.12, signifying a 112.12% drop compared to the same quarter of the previous year. Our most recent consensus estimate is calling for quarterly revenue of $130.5 million, down 68.59% from the year-ago period.
Looking at the full year, the Zacks Consensus Estimates suggest analysts are expecting earnings of $2.65 per share and revenue of $1.07 billion. These totals would mark changes of +315.45% and +56.76%, respectively, from last year.
Investors might also notice recent changes to analyst estimates for Novavax. These revisions help to show the ever-changing nature of near-term business trends. Therefore, positive revisions in estimates convey analysts' confidence in the business performance and profit potential.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. To utilize this, we have created the Zacks Rank, a proprietary model that integrates these estimate changes and provides a functional rating system.
The Zacks Rank system, ranging from #1 (Strong Buy) to #5 (Strong Sell), possesses a remarkable history of outdoing, externally audited, with #1 stocks returning an average annual gain of +25% since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has moved 34.42% higher. As of now, Novavax holds a Zacks Rank of #3 (Hold).
Looking at valuation, Novavax is presently trading at a Forward P/E ratio of 2.45. For comparison, its industry has an average Forward P/E of 19.05, which means Novavax is trading at a discount to the group.
Investors should also note that NVAX has a PEG ratio of 0.06 right now. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company's expected earnings growth rate. The Medical - Biomedical and Genetics industry had an average PEG ratio of 1.35 as trading concluded yesterday.
The Medical - Biomedical and Genetics industry is part of the Medical sector. This group has a Zacks Industry Rank of 83, putting it in the top 34% of all 250+ industries.
The Zacks Industry Rank assesses the strength of our separate industry groups by calculating the average Zacks Rank of the individual stocks contained within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Make sure to utilize Zacks.com to follow all of these stock-moving metrics, and more, in the coming trading sessions.